A Pt(IV) prodrug was attached to Human serum albumin (HSA) that protected it from premature reduction before being uptaken by cells and improved cancer targeting efficacy (Desai et al., 2006; Neumann et al., 2010; Zheng et al., 2014; Lee et al., 2015). This evidence concerns the gene ALB and cancer.